BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 29970660)

  • 1. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
    Wei J; Li H; Li C
    J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
    Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
    World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
    Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
    Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
    World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D; Zuo H; Liu L; Dong J; Ding L
    Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study.
    De Santis A; Iegri C; Kondili L; Riggio O; Salvatori FM; Catalano C; Di Martino M; Bassanelli C; Lupo M; Lucatelli P; Attili AF
    Dig Liver Dis; 2014 Aug; 46(8):726-30. PubMed ID: 24893685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Qiu B; Li K; Dong X; Liu FQ
    Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1372-1382. PubMed ID: 28488102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Use of Transjugular Intrahepatic Portosystemic Shunt and Transarterial Chemoembolization in the Treatment of Esophageal and Gastric Variceal Bleeding: A Retrospective Study of 80 Patients with Hepatocellular Carcinoma and Portal Hypertension.
    Zou X; Xue M; Li J
    Med Sci Monit; 2021 Nov; 27():e934436. PubMed ID: 34840325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary application of transjugular intrahepatic portosystemic shunt in individualized treatment of patients with cirrhotic portal hypertension complicated with refractory ascites and variceal hemorrhage].
    Jiang MM; Xu H; Zhang QQ; Wei N; Xu W; Cui YF; Liu HT; Zu MH; Wang WL; Gao ZK
    Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(47):3737-3740. PubMed ID: 31874500
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term clinical outcome and survival predictors in patients with cirrhosis after 10-mm-covered transjugular intrahepatic portosystemic shunt.
    Tejedor-Tejada J; Fuentes-Valenzuela E; García-Pajares F; Nájera-Muñoz R; Almohalla-Álvarez C; Sánchez-Martín F; Calero-Aguilar H; Villacastín-Ruiz E; Pintado-Garrido R; Sánchez-Antolín G
    Gastroenterol Hepatol; 2021 Nov; 44(9):620-627. PubMed ID: 33249114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma.
    Bettinger D; Knüppel E; Euringer W; Spangenberg HC; Rössle M; Thimme R; Schultheiß M
    Aliment Pharmacol Ther; 2015 Jan; 41(1):126-36. PubMed ID: 25329493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis.
    Zhao JB; Feng C; Zhu QH; He XF; Li YH; Chen Y
    World J Gastroenterol; 2014 Feb; 20(6):1602-7. PubMed ID: 24587637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of transjugular intrahepatic portosystemic shunt treatment of patients with liver cirrhosis and portal hypertension: Case series.
    Zheng D; Yu J; Li H; Gan H; Wang J; Jiang T; Ren H; Wu F
    Medicine (Baltimore); 2021 Jul; 100(27):e26610. PubMed ID: 34232216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.
    Chen R; Luo L; Zhang YZ; Liu Z; Liu AL; Zhang YW
    World J Gastroenterol; 2024 Apr; 30(13):1859-1870. PubMed ID: 38659484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of transjugular intrahepatic portosystemic shunt for treatment of variceal bleeding in patients with cirrhosis with or without spontaneous portosystemic shunt.
    Leng X; Zhang F; Zhang M; Guo H; Yin X; Xiao J; Wang Y; Zou X; Zhuge Y
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):853-858. PubMed ID: 30633039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects and complications of the transjugular intrahepatic portosystemic shunt: a single-centre experience.
    Kraglund F; Jepsen P; Amanavicius N; Aagaard NK
    Scand J Gastroenterol; 2019 Jul; 54(7):899-904. PubMed ID: 31203699
    [No Abstract]   [Full Text] [Related]  

  • 19. Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: A preliminary study.
    Dong H; Zhang C; Li Z; Yang H; Wang Y; Liu J; Liu B; Mao S
    J Cancer Res Ther; 2021 Jul; 17(3):784-789. PubMed ID: 34269314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.
    Bai M; He CY; Qi XS; Yin ZX; Wang JH; Guo WG; Niu J; Xia JL; Zhang ZL; Larson AC; Wu KC; Fan DM; Han GH
    World J Gastroenterol; 2014 Jan; 20(3):774-85. PubMed ID: 24574750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.